Statins and venous leg ulcer healing: Secondary analysis of data from a cohort of three randomised controlled trials

2021 ◽  
Author(s):  
Andrew Jull ◽  
Han Lu ◽  
Yannan Jiang
Keyword(s):  
Ulcer Healing ◽  
Randomised Controlled Trials ◽  
Secondary Analysis ◽  
Leg Ulcer ◽  
Controlled Trials ◽  
Venous Leg Ulcer ◽  
Randomised Controlled

scholarly journals Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials

2018 ◽  
Vol 53 (2) ◽  
pp. 1800973 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Carole Wolffenbuttel ◽  
Claudine A. Blum ◽  
Christine Baumgartner ◽  
Beat Mueller ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Randomised Controlled Trials ◽  
Secondary Analysis ◽  
Community Acquired Pneumonia ◽  
Fibroblast Growth Factor 21 ◽  
Controlled Trials ◽  
Fibroblast Growth ◽  
Randomised Controlled ◽  
Clinical Stability

Acute systemic inflammatory conditions are accompanied by profound alterations of metabolism. However, the role of fibroblast growth factor 21 (FGF21), a recently identified central regulator of metabolism, is largely unknown in community-acquired pneumonia (CAP). This study aims to characterise the pattern of FGF21 in pneumonia and associations with disease severity and outcome.This is a secondary analysis of two independent multicentre randomised controlled trials in patients presenting to the emergency department with CAP. Primary and secondary efficacy parameters included 30-day mortality, length of hospital stay, time to clinical stability and duration of antibiotic treatment.A total of 509 patients were included in the analysis. FGF21 levels at admission strongly correlated with disease severity, as measured by the Pneumonia Severity Index. Increased levels of FGF21 were associated with prolonged time to clinical stability, antibiotic treatment and hospitalisation. FGF21 levels at admission were significantly higher in nonsurvivors than in survivors, yielding a 1.61-fold increased adjusted odds ratio of 30-day mortality (95% CI 1.21–2.14; p=0.001). Moreover, FGF21 was found to identify patients for 30-day mortality with superior discriminative power compared with routine diagnostic markers.Moderate-to-severe CAP patients with higher levels of FGF21 were at increased risk for clinical instability, prolonged hospitalisation and 30-day all-cause mortality.

Sign in / Sign up

Export Citation Format

Share Document